Services (VS) of the Animal and Plant Health Inspection Service (APHIS).
The effects of recent changes in the Virus-Serum-Toxin Act (VSTA) on the control of conventional and rDNA veterinary biological products will be reviewed. The impact of proposed changes in the National Institutes of Health (NIH) guidelines and the effect of recent administrative changes within USDA on the review of conventional and rDNA products by Veterinary Services will also be discussed.
Regulation of rDNA-derived products is based on the principle that these new products are not significantly different from similar products produced by conventional methods. Thus, existing statutes provide a basic network of agency jurisdiction over both research and products. This existing network has been used to form a coordinated framework for regulating biotechnology products and research in the United States.
Current authorities and regulatory jurisdictions for biotechnology products were defined in two Federal Register publications. A proposed coordinated framework for regulating biotechnology was published on 31 December 1984. This was followed on 26 June 1986 by a document describing the regulatory policies of the individual Federal departments and the policies for review of research conducted or supported within these departments.
To coordinate and develop a policy for implementing these authorities, an interagency science coordinating mechanism -the Biotechnology Science Coordinating Committee (BSCC) -was established in October 1985 ( 
Coordinated framework
This Committee provides a context for the sharing of information concerning scientific developments among various agencies and the coordination of biotechnology policy on a national level. Members of the BSCC are senior policy officials from USDA, Health and Human Services, Environmental Protection Agency, and National Science Foundation. The BSCC is currently chaired by Dr David Kingsbury of the National Science Foundation (Assistant Director of Biological, Behavioral and Social Sciences).
Within the USDA an additional coordinating structure has been developed. The Office of Agriculture Biotechnology (OAB) was established by Secretary of Agriculture Richard Lyng in July 1986 (Fig. 2) 2. It also provides staff support for the Agricultural Biotechnology Recombinant DNA Advisory Committee (ABRAC) which reviews USDA-funded research proposals or when requested, license applications.
3. It acts as a repository of biotechnology information received from USDA agencies responsible for the review of applications, and the issue of permits or licenses.
The Biotechnology and Environmental Coordination Staff (BECS) was established in July 1985 to coordinate the development and implementation of biotechnology policy and the coordination of biotechnology regulatory activities in USDA (Fig. 3) . It also provides advice and council to program staffs in preparing environmental documents required by the National Environmental Policy Act (NEPA) of 1969, and reviews these documents before being sent outside APHIS. 
Regulatory agencies
VS has extended this coordinating structure by establishing a Veterinary Services Biotechnology Committee (Tables I and II) . This committee considers the development and application of new biotechnology policy related to the mission of VS, and provides recommendations to the Deputy Administrator. The committee is chaired by the Associate Deputy Administrator, VS, and has members representing VS Program Planning and Development, VS Biologics Staff, Agriculture Research Service, Food Safety and Inspection Service, National VS Laboratories, National Institutes of Health (NIH) -Recombinant DNA Advisory Committee, Food and Drug Administration, and the Office of the General Counsel (OGC). This committee reviews proposed rule making, memoranda, and other policy-making documents concerning biotechnology before publication, and also reviews Environmental Assessments (EA) prepared by the VS Biologics Staff before agency authorization of shipment of live recombinant vaccines for use outside contained premises.
In establishing the VS Biotechnology Committee, VS has become intimately involved in biotechnology issues and policy-making, primarily because of its responsibility for regulating veterinary biological products under the Virus-SerumToxin Act of 1913. VS has regulated the import and interstate movement of veterinary biological products under this act for over 70 years. As new production technologies have emerged, the agency has had to respond with new regulatory procedures. The development of new procedures applicable to recombinant-derived products is but the most recent change.
It has been, and still is the attitude of the agency that new biotechnology products do not differ significantly from products produced by conventional methods. The emphasis is on the product and its intended use rather than the method used in development. Each product must be considered on a case-by-case basis. 
Functions of the VS Biotechnology Committee
• Coordinate and review biotechnology issues and policy.
• Review VS biotechnology regulatory policies and procedures.
• Review and recommend procedures for implementing VS biotechnology policy.
• Review and refer issues involving departmental and agency biotechnology policy to APHIS BECS.
• Review biotechnology issues referred to VS from BECS and other agencies and recommend response by the Deputy Administrator.
• Interact with APHIS BECS.
• Consider other issues as directed by the Deputy Administrator.
For the purposes of licensing under the VSTA, veterinary biological products derived by recombinant-DNA techniques or developed from hybridomas are classified into three broad categories, depending on the biological characteristics of the new products and on safety aspects (Table III) . This approach is very similar to the one used for conventional veterinary biologies. Category II:
• Vaccines containing live organisms modified by gene insertion or deletion
Category III:
• Vaccines using live vectors to carry r-derived foreign genes Category I comprises inactivated products prepared from recombinant DNAderived vaccines, viruses, bacterins, bacterin-toxoids, virus subunits, or bacterial subunits (Table IV) . These nonviable or killed products pose no risk to the environment and present no new or unusual safety concerns. Monoclonal antibody (hybridoma) products used prophylactically, therapeutically, or as components of diagnostic kits are also included in this category (Tables V and VI) . Category II comprises products containing live micro-organisms that have been modified by adding or deleting one or more genes (Table VII) . Deleted genes may code for virulence, oncogenicity, enzyme activity, or other biochemical functions. Added genes may result in the expression of unique marker antigens or the production of novel biochemical by-products. Precautions must be taken to ensure that this The genetic information to be added or deleted in this category must consist of well-characterized DNA segments. Required licensing data may include base pair analysis, sequence information, restriction endonuclease sites, as well as phenotypic characterization of the altered organism. A comparison is also required between the engineered organism and its parent strain with respect to biochemical pathways, virulence traits, or other factors affecting pathogenicity. Current policy requires an Environmental Assessment or decision document to be prepared before these products can be considered for experimental field trial or licensing.
Category III consists of products using live vectors to carry recombinant-derived foreign genes that code for immunizing antigens and/or other immune stimulants. Live vectors may carry multiple recombinant-derived foreign genes and are capable of efficiently infecting and immunizing host animal species. Two classes of viral vectors are currently being used, the lytic viruses (such as polyoma and SV-40) and the socalled shuttle vectors based on retroviruses. Live vectors currently being evaluated include vaccinia virus, bovine papillomavirus, herpesviruses, adenoviruses, SV-40 virus, and yeasts. When used as live vectors of foreign genes, the new rDNA organisms must be fully recharacterized and compared with the parent virus. Concerns for safety to humans and animals, and impact on the environment, must be addressed in an Environmental Assessment or Environmental Impact Statement before such products can be considered for experimental field trial or licensing.
A notice of proposed actions under NIH guidelines for research involving recombinant DNA molecules was published in the Federal Register on 19 December 1986. This notice proposed a revision of sections I-B and III-A-2 of the guidelines concerning experiments, which would require RAC review, and NIH and Institutional Biosafety Committee (IBC) approval before initiation. This proposal would exempt research involving "deletion derivatives not otherwise covered by these guidelines" from NIH review or approval. It is also proposed that in the definition of rDNA the word "foreign" would be clarified by the footnote: "Rearrangements involving the introduction of DNA from different organisms or different strains of an organism will be considered recombinant DNA. Deletions, single-base changes and rearrangements within a single genome will not involve the introduction of foreign DNA and therefore would not be considered recombinant DNA". Further, it proposed that releases into the environment would not require NIH review and approval for organisms resulting from "deletion derivatives and single base changes not otherwise covered by the guidelines" and "rearrangements and amplification within a single genome. Rearrangement involving the introduction of DNA from different strains of the same organism would not be covered by this exemption". The proposed modification of Section III-A-2 also provides a clear, concise and much needed clarification of the position whereby the term "deliberate release" essentially describes or suggests a dangerous event and is therefore inappropriate for describing the use of rDNA products outside contained premises. The proposal to describe such release as "planned introduction" under accepted scientific practices in which there is adequate evidence of biological and/or physical control of the recombinant organism is consistent with the USDA position concerning release.
If these proposed changes in the NIH guidelines are accepted and finalized, VS may need to consider amending its current classification scheme for rDNA products in favor of a scheme with only two categories (Table VIII) . Category II:
• Vaccines using live vectors to carry r-derived foreign genes • Vaccines containing live organisms modified by gene insertion or deletion (introduction of "foreign" DNA)
Category I could consist of rDNA-derived inactivated products, monoclonal antibody products, and virus or bacterial subunits as defined for the current category I, and live products containing organisms resulting from deletions, single base changes and rearrangements within a single genome. It may be appropriate that a categorical exemption be requested from compliance with the National Environmental Policy Act (NEPA) for products in this category since they would be exempt from NIH review. If exempted from NEPA, release of these products would require only demonstration of purity, safety, potency and efficacy as required presently under the VSTA for conventional live products. Data submitted to establish environmental safety for the live products in this category could be documented in a decision document instead of preparing an Environmental Assessment (EA).
Category II would include live vectors carrying one or more foreign genes coding for immunizing antigens and/or drugs, and organisms resulting from rearrangements and amplifications involving the introduction of DNA from different organisms or different strains of the same organism. This category would include the current category III products plus the true recombinant products in the current category II.
Concerns for safety to humans and animals as well as environmental impact would have to be addressed in an EA or Environmental Impact Statement before these products could be considered for experimental field use or licensing.
In the regulation of rDNA veterinary biologics, as with other rDNA-derived products, public concern has focused on procedures for regulating release of these products from containment. Concern has been expressed regarding the adequacy of current law to require review and evaluation of rDNA products prior to release, to cover all rDNA deserving attention, and to assure protection of public health and the environment. The need for peer review, public notification, and documentation in these decisions has also been expressed. Veterinary Services has established procedures for regulating veterinary biological products which address all of these concerns in a positive manner, by means of an amendment to the VSTA contained in the Food Security Act of 1985, publication of new regulations to implement this amendment, and implementation of new administrative procedures for the review of products (Table IX) . In amending the VSTA of 1913, the Food Security Act of 1985 expanded the Department's authority over veterinary biological products in several respects. Under the amended statute it is unlawful to ship or deliver for shipment any worthless, contaminated, dangerous or harmful veterinary biologies intended for the treatment of animals anywhere in or from the United States. Previously, intrastate shipments and exports were not subject to the VSTA. The amendment also expanded the Secretary's rule-making authority, authorized the inspection of any establishment preparing animal biologies and provided new authorities of detention, seizure, and condemnation of products. With these changes in the statutes, VS gained the broad authority needed for supervision of all biological products shipped in the United States.
To implement this new authority, several new and amended regulations have been promulgated. Title 9 CFR, Part 103.3 which contains widely used provisions for the interstate shipment of unlicensed biological products for experimental purposes, such as field safety testing before licensing, was amended. Regulations now require authorization from the Deputy Administrator before any shipment of an experimental product in or from the United States, including intrastate and export shipments. These amended regulations now permit VS to supervise all experimental uses of veterinary biological products outside containment, whether in the United States or for export.
As with conventional products, rDNA products must be shown to be pure, safe, potent and efficacious, and not worthless, contaminated, dangerous or harmful. Assurance of safety in all products has included the responsibility to ensure that products do not have any adverse effects upon the environment and do not harm animal and human health. To ensure that safety concerns are fully respected, regulations have also been amended to require a person wishing to import or ship a veterinary biological product anywhere in or from the United States to provide any additional information needed by the Deputy Administrator for a proper assessment of the impact of products on the environment. Such additional information will apply to live vaccines and may include (but is not necessarily limited to) demonstrating nonpathogenicity and nonreversion to virulence by means of a number of backpassages in the host animal; also studies to determine the fate of the organism when injected into the host, and the ability of the organism to shed, transmit, and maintain itself in a livestock population. Persons may also be requested to define the stability and survival of the organism in the environment.
The organism's host range and ability to adapt to and affect other species may also need to be investigated. In the case of live rDNA products (current category II and III products) Veterinary Services will use these data to prepare a decision document or an Environmental Assessment in accordance with the National Environmental Policy Act. Under current policy, shipments of live rDNA products that involve release of product outside containment will not be authorized until the completion of an EA and the determination of a finding of no significant impact (FONSI) by the Deputy Administrator. Product is not permitted to be shipped for release outside of containment until 30 days after the publication in the Federal Register of a notice of the availability of the EA and FONSI (Fig. 4) .
Environmental assessments are prepared by the VS Biologics Staff, reviewed by the BEC Staff for compliance with NEPA and departmental biotechnology policy, reviewed by the OGC for legal correctness, and evaluated by the VS Biotechnology Committee for technical sufficiency and adequacy of the findings. The determination of a FONSI is made by the Deputy Administrator only after concurrence in the EA and findings from all parties. Implementation of the NEPA process in this manner provides for review, documentation of the decision-making process, and notification of the public before authorization of use of such products outside containment. This process has been applied successfully to recent field trials authorized for a live recombinant-derived Pseudorabies vaccine produced by the UpJohn Company and the Diamond Scientific Company. Requests to release other rDNA products are currently under review. It is anticipated that several new rDNA products will be authorized for use outside containment in this manner in the future.
Proposed changes in section I-A of the NIH guidelines, as contained in the Federal Register Notice of 19, December 1986, also may have a significant impact on VS procedures for handling rDNA products. The proposed changes would permit any rDNA experiments, which according to the guidelines require NIH approval, to be sent either to NIH for approval or another Federal agency which has jurisdiction for review and approval. If submitted to and approved by another Federal agency, experiments could proceed without the necessity for NIH review or approval. Our agency supports this change. It would be consistent with the development of expanded regulatory authority in other Federal agencies. It would also help eliminate overlapping jurisdiction and possible confusion concerning which agency an experiment should APHIS review procedures for field testing live rDNA products be submitted to for review and approval. At present, there is no provision or requirement for transfer of information between NIH and other Federal regulatory agencies. Because the review by another Federal agency serves the same purpose as that currently conducted by NIH, it would be superfluous to require overlapping reviews. Each Federal regulatory agency may also have unique requirements or criteria for review not normally demanded by NIH that would also need to be addressed.
Currently, the NIH guidelines presented in Appendix L provide only the conditions under which plants containing recombinant DNA molecules may be released into the environment. The RAC Working Group on Definitions, meeting in December 1986, recommended the establishment of new appendices, similar to Appendix L, to include conditions of release for genetically-engineered animals, micro-organisms other than vaccines, and vaccines.
We favor the proposal by the RAC Working Group on Definitions to amend Section III-A-2 by adding parallel sections to be written as Appendices M, N, and O to cover (respectively) animals, micro-organisms (other than vaccines), and vaccines. We also urge appropriate Federal, private, and public involvement in the preparation of the criteria for these new Appendices.
Another paper provides more detailed information regarding VS guidelines for transferring live, genetically-engineered organisms from containment to limited field trials.
Although further refinements and adjustments may be necessary as our knowledge of rDNA products expands, we feel procedures for review and approval of rDNA veterinary biological products that have been established in the United States provide an appropriate balance of flexibility and control, and as a result, new rDNA products should be marketed in a manner that maintains the public confidence. 
